Small molecule research from hit finding through to preclinical development
BioNTech Small Molecule´s research activities are focused on innovative therapies for cancer indications, with a special interest in immuno oncology. Our expertise in drug discovery of small molecules in these therapeutic areas has been proven by several of our discovery projects having successfully reached preclinical and clinical stage. We will continue to engage in the discovery of novel drug candidates for the enhancement of BioNTech’s clinical development pipeline.
Through current and former collaborations, scientists have additionally acquired a strong expertise in customer orientated research programs covering a multitude of
therapeutic areas and target classes (proteases, kinases, phosphatases, GPCRs, ion channels, etc.) from hit identification up to the characterization of development candidates. Efficient data management and intensive communication between experts from different fields as well as dedicated project management guarantee fast and effective advancement of our proprietary and our customers’ projects. Our research service offering covers major scientific aspects of drug discovery: computational chemistry, medicinal and analytical chemistry. As part of integrated drug discovery services, we also provide formulation development, pharmacokinetic and toxicological experiments. A close network of collaborating biologists and pharmacologists has been established.
Our Vision is…
… to use our platform for fast and efficient supply of small molecule agents for our development pipeline.
… to make our platform the priority research engine for our customers.